Detailed Mechanism Funding and Narrative

Years of mechanism: 2011 2012 2013 2014 2015 2016

Details for Mechanism ID: 13047
Country/Region: Uganda
Year: 2015
Main Partner: Makerere University
Main Partner Program: School of Medicine
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $9,518,235 Additional Pipeline Funding: $3,079,946

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $781,109
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $431,845
Care: Pediatric Care and Support (PDCS) $455,048
Laboratory Infrastructure (HLAB) $1,204,811
Strategic Information (HVSI) $75,053
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $160,640
Testing: HIV Testing and Counseling (HVCT) $1,090,346
Sexual Prevention: Other Sexual Prevention (HVOP) $713,491
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $134,945
Treatment: Adult Treatment (HTXS) $4,400,435
Treatment: Pediatric Treatment (PDTX) $70,512
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 3,289
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 12,758
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 333
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 1,297
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 6,420
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 24,908
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 396
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 1,540
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 10,438
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 40,503
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 10,438
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2016 40,503
CARE_NEW Aggregated Age/sex: <15 Female 2016 210
CARE_NEW Aggregated Age/sex: <15 Male 2016 184
CARE_NEW Aggregated Age/sex: 15+ Female 2016 3,633
CARE_NEW Aggregated Age/sex: 15+ Male 2016 1,974
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 6,001
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 6,001
CARE_NEW Sum of Aggregated Age/sex disaggregates 2016 6,001
FN_THER Aggregated Age: <18 2016 376
FN_THER Aggregated Age: 18+ 2016 595
FN_THER Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period 2016 971
FN_THER Number of PLHIV who were nutritionally assessed and found to be clinically undernourished 2016 12,147
FN_THER Sum of Aggregated Age disaggregates 2016 971
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 5,265
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2016 4,983
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 3,975
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2016 3,755
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 40,227
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2016 37,948
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 28,987
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2016 27,362
HTS_TST By Test Result: Negative 2016 75,564
HTS_TST By Test Result: Negative 2016 71,593
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 78,454
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2016 74,048
HTS_TST Sum of Aggregated Age/Sex <15 2016 9,240
HTS_TST Sum of Aggregated Age/Sex <15 2016 8,738
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 69,214
HTS_TST Sum of Aggregated Age/Sex 15+ 2016 65,310
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 78,454
HTS_TST Sum of Aggregated Age/Sex disaggregates 2016 74,048
HTS_TST Sum of Test Result disaggregates 2016 78,454
HTS_TST Sum of Test Result disaggregates 2016 74,048
HTS_TST_POS By Test Result: Positive 2016 2,890
HTS_TST_POS By Test Result: Positive 2016 2,455
LAB_ACC Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation 2016 1
LAB_CAP By clinical laboratories 2016 3
LAB_CAP Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests 2016 3
OVC_ACC Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services 2016 8,530
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 2,974
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 2,974
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 2,466
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 508
PMTCT_ARV Sum of New and Current disaggregates 2016 2,974
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 236
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 2,381
PMTCT_EID Sum of Infant Age disaggregates 2016 2,381
PMTCT_STAT By: Known positives at entry 2016 2,466
PMTCT_STAT By: Number of new positives identified 2016 508
PMTCT_STAT Number of new ANC and L&D clients 2016 26,423
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 24,738
PMTCT_STAT Sum of Positives Status disaggregates 2016 2,974
PP_PREV Age/sex: 10-14 Female 2016 3,636
PP_PREV Age/sex: 10-14 Male 2016 2,802
PP_PREV Age/sex: 15-19 Female 2016 7,022
PP_PREV Age/sex: 15-19 Female 2016 254
PP_PREV Age/sex: 15-19 Male 2016 5,898
PP_PREV Age/sex: 15-19 Male 2016 290
PP_PREV Age/sex: 20-24 Female 2016 10,366
PP_PREV Age/sex: 20-24 Female 2016 374
PP_PREV Age/sex: 20-24 Male 2016 6,839
PP_PREV Age/sex: 20-24 Male 2016 314
PP_PREV Age/sex: 25-49 Female 2016 14,940
PP_PREV Age/sex: 25-49 Female 2016 544
PP_PREV Age/sex: 25-49 Male 2016 11,281
PP_PREV Age/sex: 25-49 Male 2016 555
PP_PREV Age/sex: 50+ Female 2016 1,005
PP_PREV Age/sex: 50+ Female 2016 36
PP_PREV Age/sex: 50+ Male 2016 903
PP_PREV Age/sex: 50+ Male 2016 48
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 64,692
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2016 2,415
PP_PREV Sum of Age/Sex disaggregates 2016 64,692
PP_PREV Sum of Age/Sex disaggregates 2016 2,415
TB_ART Aggregated Age: <15 2016 20
TB_ART Aggregated Age: 15+ 2016 232
TB_ART Female 2016 163
TB_ART Male 2016 89
TB_ART Sum of Aggregated Age disaggregates 2016 252
TB_ART Sum of Sex disaggregates 2016 252
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2016 318
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2016 252
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2016 2,834
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2016 37,669
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 10,438
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2016 40,503
TB_SCREEN Sex: Female 2016 26,450
TB_SCREEN Sex: Male 2016 14,053
TB_SCREEN Sum of Aggregated Age disaggregates 2016 40,503
TB_SCREEN Sum of Sex disaggregates 2016 40,503
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2016 40,503
TX_CURR Aggregated Age/Sex: 15+ Female 2016 11,119
TX_CURR Aggregated Age/Sex: 15+ Male 2016 24,164
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 38,086
TX_CURR Sum of Aggregated Age/Sex 15+ 2016 35,283
TX_CURR Sum of Aggregated Age/Sex disaggregates 2016 35,283
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2016 2,943
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2016 6,208
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 9,545
TX_NEW Sum of Aggregated Age/Sex disaggregates 2016 9,151
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 4,886
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 5,748
VMMC_AE Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) 2016 2,756
VMMC_CIRC By circumcision technique: Surgical VMMC 2016 8,351
VMMC_CIRC By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery 2016 8,351
VMMC_CIRC By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site 2016 1,837
VMMC_CIRC By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program) 2016 6,364
VMMC_CIRC By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site) 2016 150
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2016 8,351
Cross Cutting Budget Categories and Known Amounts Total: $1,350,000
Key Populations: MSM and TG $100,000
Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: Sex Workers $500,000
Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Gender: Gender Based Violence (GBV) $500,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $250,000
Changing harmful gender norms and promoting positive gender norms
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Increase gender-equitable access to income and productive resources, including education
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Monitoring and Evaluation